About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Aug 19, 2019 11:59 am | Healthcare Staffing, Other Services, Private Equity
As healthcare companies and providers across the industry wrestle with staffing shortages and retention, staffing firms are looking to fill some of the gaps, thus driving M&A activity. According to our Deal Search Online database, there have been nine acquisitions... Read More »
by Dylan Sammut | Aug 19, 2019 11:08 am | eHealth
Experian Health, the healthcare arm of Experian (LSE: EXPN) announced earlier this month that it acquired MyDirectHealth, a digital health firm. No financial terms were disclosed. Companies like Experian Health that collaborate with hospitals and provide data support... Read More »
by Dylan Sammut | Aug 19, 2019 8:46 am | Healthcare Market Updates
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online... Read More »
by Dylan Sammut | Aug 12, 2019 10:17 am | Laboratories, MRI & Dialysis, Medical Devices, Private Equity
After a nearly two-year hiatus, the diagnostic and therapeutic imaging giant Siemens Healthineers AG (XETRA: SHL.DE) has agreed to purchase Corindus Vascular Robotics, Inc. (NYSE: CVRS) for $1.1 billion, at a price of $4.28 per share. Corindus is a global leader in... Read More »
by Dylan Sammut | Aug 12, 2019 10:13 am | CRO, Other Services, Private Equity
This past week Permira, a global investment firm based in the United Kingdom, spent $2.4 billion for Cambrex Corporation (NYSE: CBM). Cambrex is a premier contract development and manufacturing organization (CDMO) in the small molecule space and provides drug... Read More »